Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.

Li L, Eid JE, Paz AC, Trent JC.

BioDrugs. 2017 Oct;31(5):379-392. doi: 10.1007/s40259-017-0237-2. Review.


VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):329-334.e1. doi: 10.1016/j.clml.2016.02.042. Epub 2016 Mar 4.


A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.

Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016. Epub 2014 Jul 8.


Reprogramming of mesenchymal stem cells by oncogenes.

Eid JE, Garcia CB.

Semin Cancer Biol. 2015 Jun;32:18-31. doi: 10.1016/j.semcancer.2014.05.005. Epub 2014 Jun 2. Review.


Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC.

Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19.


Targeting the Wnt pathway in synovial sarcoma models.

Barham W, Frump AL, Sherrill TP, Garcia CB, Saito-Diaz K, VanSaun MN, Fingleton B, Gleaves L, Orton D, Capecchi MR, Blackwell TS, Lee E, Yull F, Eid JE.

Cancer Discov. 2013 Nov;3(11):1286-301. doi: 10.1158/2159-8290.CD-13-0138. Epub 2013 Aug 6.


Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY.

J Clin Oncol. 2013 Jul 1;31(19):2485-92. doi: 10.1200/JCO.2012.45.5766. Epub 2013 May 28.


Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2.

Garcia CB, Shaffer CM, Alfaro MP, Smith AL, Sun J, Zhao Z, Young PP, VanSaun MN, Eid JE.

Oncogene. 2012 May 3;31(18):2323-34. doi: 10.1038/onc.2011.418. Epub 2011 Sep 26.


A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.

Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K, McCarthy CD, Gore L.

Clin Cancer Res. 2010 Apr 15;16(8):2458-65. doi: 10.1158/1078-0432.CCR-09-3220. Epub 2010 Apr 6.


The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1.

Barco R, Garcia CB, Eid JE.

PLoS One. 2009;4(4):e5060. doi: 10.1371/journal.pone.0005060. Epub 2009 Apr 1.


The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells.

Chittezhath M, Frump AL, Jourquin J, Lobdell N, Eid JE.

Exp Cell Res. 2008 Nov 15;314(19):3551-62. doi: 10.1016/j.yexcr.2008.09.006. Epub 2008 Sep 20.


DC-Dielectrophoretic separation of biological cells by size.

Kang Y, Li D, Kalams SA, Eid JE.

Biomed Microdevices. 2008 Apr;10(2):243-9.


The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway.

Barco R, Hunt LB, Frump AL, Garcia CB, Benesh A, Caldwell RL, Eid JE.

Mol Biol Cell. 2007 Oct;18(10):4003-12. Epub 2007 Aug 8.


The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex.

Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE.

Oncogene. 2006 Jun 22;25(26):3661-9. Epub 2006 Feb 6.


Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.

Huang Y, Ananthakrishnan T, Eid JE.

Am J Hematol. 2003 Oct;74(2):125-6.


p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion.

Eid JE, Kung AL, Scully R, Livingston DM.

Cell. 2000 Sep 15;102(6):839-48.


Gossypol-induced death of African trypanosomes.

Eid JE, Ueno H, Wang CC, Donelson JE.

Exp Parasitol. 1988 Jun;66(1):140-2. No abstract available.


Supplemental Content

Support Center